Hims, Novo Nordisk

Hims & Hers will start selling a generic weight loss drug
The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The news comes as some patients still struggle to fill prescriptions of the most advanced branded GLP-1 treatments on the market like Zepbound,
Hims & Hers Health plans to offer generic version of Novo Nordisk's drug
Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication kits at $79 per month
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025.It reported strong quarterly earnings. The stock rose 8.
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025. "We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation,
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.
Hims & Hers shares rally on results, but execs say GLP-1 drug shortage ‘is not abating’
Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...
Hims & Hers to launch a generic for Novo’s older GLP-1
Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...
Becker's Hospital Review2h
Hims & Hers to sell generic weight loss drug in 2025
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Modern Healthcare14h
Hims & Hers defends compounded GLP-1s as shortages wane
Compounded GLP-1s are essentially copies of popular weight loss medications made by manufacturers such as Novo Nordisk and Eli Lilly. Hims & Hers CEO Andrew Dudum said during the company's third ...
Seeking Alpha20h
Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow
HIMS boasts high gross margins (~80%) with no R&D risk, capitalizing on the shift away from traditional pharmacies to ...
Hims & Hers Health jumps on earnings. CFO talks GLP-1 influences.
Hims & Hers Health (HIMS) shares jumped in extended trading after the company reported better than expected third quarter ...
Hims & Hers stock could dive soon despite strong results
Hims & Hers (HIMS) stock price remained on edge even after the fast-growing telehealth company published strong financial ...
Jonna Kim’s Buy Recommendation: Hims & Hers Health’s Robust Growth Trajectory and Market Potential
TD Cowen analyst Jonna Kim maintained a Buy rating on Hims & Hers Health (HIMS – Research Report) today and set a price target of ...
Hims & Hers Health: Another Blowout Quarter Ignored
Hims & Hers Health exceeded revenue expectations, achieved substantial subscriber growth, and remains undervalued in the ...